Scorpius Holdings, Inc. (SCPX)
NYSEAMERICAN: SCPX · Real-Time Price · USD
0.670
+0.010 (1.52%)
At close: Nov 20, 2024, 4:00 PM
0.684
+0.014 (2.06%)
After-hours: Nov 20, 2024, 7:50 PM EST
Scorpius Holdings Revenue
Scorpius Holdings had revenue of $922.37K in the quarter ending September 30, 2024, with 27.55% growth. This brings the company's revenue in the last twelve months to $10.04M, up 351.08% year-over-year. In the year 2023, Scorpius Holdings had annual revenue of $6.99M with 1,789.60% growth.
Revenue (ttm)
$10.04M
Revenue Growth
+351.08%
P/S Ratio
0.13
Revenue / Employee
$119,575
Employees
84
Market Cap
2.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 6.99M | 6.62M | 1,789.60% |
| Dec 31, 2022 | 370.18K | -1.74M | -82.48% |
| Dec 31, 2021 | 2.11M | -835.16K | -28.33% |
| Dec 31, 2020 | 2.95M | -101.14K | -3.32% |
| Dec 31, 2019 | 3.05M | -2.74M | -47.37% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Venus Concept | 67.20M |
| Xylo Technologies | 57.64M |
| Akanda | 2.51M |
| Biodexa Pharmaceuticals | 104.90K |
| Sonnet BioTherapeutics Holdings | 55.88K |
SCPX News
- 2 days ago - Scorpius Holdings Launches Scorpius Ventures to Support U.S. Biotech Innovation through Flexible Equity-Based Onshoring Model - GlobeNewsWire
- 6 days ago - Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability - GlobeNewsWire
- 17 days ago - Scorpius Holdings Announces Collaboration with Celltheon Corporation, a U.S.-Based Cell Line Development Company; First Client Signed Under New Partnership Agreement - GlobeNewsWire
- 21 days ago - Scorpius Holdings Announces Implementation of New Cost Savings Measures Expected to Save Over $2 Million Annually - GlobeNewsWire
- 2 months ago - Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA - GlobeNewsWire
- 3 months ago - Scorpius Holdings CEO Provides Corporate Update; Highlights Expanding Sales Pipeline, Enhanced Manufacturing Capabilities, and Path Toward Positive Cash Flow - GlobeNewsWire
- 3 months ago - Scorpius Holdings Achieves 16% Year-Over-Year Increase in Revenue for the Second Quarter of 2024 - GlobeNewsWire
- 3 months ago - Scorpius Holdings, Inc. Announces Closing of Public Offering - GlobeNewsWire